Phaseline

Targets › DHPS

DHPS (Deoxyhypusine synthase): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 4, 1 Phase 3; Infectious disease, Immunology; next expected readout Dec 2026.

Catalyzes the NAD-dependent oxidative cleavage of spermidine and the subsequent transfer of the butylamine moiety of spermidine to the epsilon-amino group of a critical lysine residue of the eIF-5A precursor protein to form the intermediate deoxyhypusine residue. This is the first step of the post-translational modification of that lysine into an unusual amino acid residue named hypusine. (UniProt, P49366)

Open in Phaseline: the race on DHPS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tongji HospitalTrimethoprim
Bacterial dihydrofolate reductase inhibitor
DHFR, DHPSPhase 4Pneumonia, PneumocystisDec 2026
Indiana UniversityTrimethoprim-sulfamethoxazole (TMP-SMX)
Dihydropteroate synthase and dihydrofolate reductase inhibitor; inhibits bacterial folate
DHPS, DHFRPhase 4Methicillin Resistant Staphylococcus AureusJun 2027
Tampere UniversitySulfadoxine
Dihydropteroate synthetase inhibitor
DHPS, DHFRPhase 3MalariaDec 2027

Conditions

Malaria (1) Pneumonia, Pneumocystis (1) Methicillin Resistant Staphylococcus Aureus (1)

Modalities

small molecule (3)

Companies

Tampere University (1) Tongji Hospital (1) Indiana University (1)

Related targets

DHFR (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.